ICU SeaStar Medical Holding Corp

$ICU I’ve been invested in potential sepsis treatments since I bought MTSB (which became CTSO) back in 2009. Back in 2011, CTSO got EU approval for a cytokine filter, very similar to the SCD, to treat sepsis. The company Mcap shot up 10X, to $300M. EU approval was based on safety data only, not efficacy. The CTSO device has not proven its efficacy for anything yet still sells $30M annually in the EU. If we get US approval for the SCD, I would expect Mcap to be $3B or greater. This current price is a steal.

$ICU remember, Trump would love a big biotech win before midterms, and midterms are < 1mo away... $SLS $IBRX $GALT

$ICU $SLS As a Biostatistician I came to $ICU in September 2025 and made some money and put it all on $SLS which went up 1000% since that move. I started a 250,000 share position today at $ICU because FDA just changed the entire game for $ICU Overnight. "This new Breakthrough Device Designation for our SCD therapy continues to exemplify the importance and critical need for an innovative therapy that can effectively treat the hyperinflammation that destroys organs and takes far too many lives each year," stated Eric Schlorff, CEO of SeaStar Medical. "Our protocol for the ongoing NEUTRALIZE-AKI pivotal clinical trial includes pre-specified statistical analysis of the subset of patients with sepsis or septic like condition, and as such, we expect to have important data to present to the FDA for this indication in the near term. $ICU SCD therapy in Adults will be a Multi Billion dollar market. ✌️🙏❤️‍🩹

$ICU solid news FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

$ICU The importance of today's BDD designation for sepsis cannot be understated. This is arguably the single most important development in the past 6 months. Here is why: In Q2 earnings, Chung stated ICU was including sepsis and ARDS patients into Neutralize AKI "A PRIORI". This means evaluating SCD benefit in sepsis is part of the PRESPECIFIED statistical plan and won't be a post hoc analysis. By granting a BDD today, the FDA is saying they acknowledge this and giving it weight. Historically, 60-70% of ICU AKI patients are due to sepsis. At 339 patients, that potentially means a "n" around 200 which is credible. By looking at sepsis data on its own merits, the FDA is saying even if the data for the overall trial does not have enough statistical significance or is borderline, the SCD will still have a path to approval on the sepsis indication alone. Translation: More shots on goal. I added 20% on the news this morning. Per usual, science is exciting, financial concerns remain.

$ICU ya know I really like that picture of the team. These are good, down to earth folks. Be proud of what you are a part of. God speed.

$ICU working on a starter position here with 10k shares. Hopefully the balance will get filled soon. Only about 2200 filled so far.

$ICU Wednsday next week. Congratulations CMO Dr. Kevin Chung, Col. US ARMY(Ret.) A well deserved award for your leadership and dedication to healing our veterans. (Note: The last 3 paragraphs illustrate his specific contributions to serious battlefield injuries and his innovations for treatment) Dr. Kevin Chung's keynote presentation and recognition ceremony at the Update in Critical Care Nephrology 2026 conference—taking place on October 14, 2026, at the Hospital Central de la Defensa in Madrid, Spain—will be managed primarily by the host organization rather than SeaStar Medical. At this conference, Dr. Chung is receiving the prestigious Combat Nephrology Award 2026 and delivering his keynote lecture, “AKI in Military Operations: From Battlefield Experience to Future Strategies,” reflecting his background as a retired U.S. Army Colonel and former Medical Director of the U.S. Army Burn ICU. Release and Coverage Details • The Host's Release: Because this is an academic meeting endorsed by the Spanish Society of Nephrology (S.E.N.), any official documentation, presentation slides, or recap media will be handled directly through the host's institutional channels and official conference registration portals. • SeaStar Medical's Role: Since this presentation focuses on Dr. Chung's historic combat casualty care expertise and military battlefield strategies rather than a regulatory or financial update for the company, SeaStar Medical is not expected to put out an immediate corporate press release for the event. Instead, updates are driven directly by the clinical community on platforms like Jesús Hernández Vaquero's Professional Updates. There is no broad public simulcast or live stream option available for the Madrid meeting, so material access will remain restricted to registered clinical attendees and subsequent post-conference educational archives published by the host. Would you like assistance in finding the official registration or program outline from the Spanish Society of Nephrology for the Madrid event, or are you looking for summaries of Dr. Chung's previously published research on combat-related AKI operations? • X Kevin K. Chung, MD () / X Nephrology 2026 … 🗓️ 14 y 15 de octubre de 2026 📍 Hospital Central de la Defensa, Madrid ➡️Programa e inscripciones: • LinkedIn·Jesús Hernández Vaquero Jesús Hernández Vaquero's Post - Dr. Kevin Chung An internationally recognized expert in burn critical care, combat casualty care, acute organ failure and extracorporeal organ sup... 1. Official Program & Registration for Madrid Event The official event in Spain is the Update in Critical Care Nephrology 2026, a premier clinical conference focused on acute kidney injury and advanced renal support in critically ill patients. • Host and Scientific Endorsements: The conference is organized at the Hospital Central de la Defensa in Madrid. It carries the scientific endorsement of both the Spanish Society of Nephrology (S.E.N.) and the Madrid Society of Nephrology (SOMANE). • Agenda Focus: The meeting runs from October 14–15, 2026. Dr. Chung's keynote session and presentation of the Combat Nephrology Award 2026 will be focal points of the opening day's itinerary. • Registration Portals: Because seating at the defense hospital facility is strictly limited, clinicians must register in advance. You can access details, local programming itineraries, and seat registration directly via the SOMANE Update CCN Portal or the broader S.E.N. Course Directory. 2. Dr. Kevin Chung’s Combat-Related AKI Research Dr. Chung's award in Madrid highlights over two decades of military medicine research pioneered during his time as a U.S. Army Colonel and Medical Director of the U.S. Army Burn Intensive Care Unit. His landmark publications reshape how clinicians manage critical kidney trauma on the battlefield: • Survival Breakthrough with Early CRRT: In a landmark study analyzing severely burned military casualties evacuated from combat theaters (Iraq and Afghanistan), Dr. Chung’s team demonstrated that early, aggressive use of continuous renal replacement therapy (CRRT) significantly dropped 28-day mortality from 75% in historical controls down to 22% in the treatment group. This established CRRT as a vital stabilization tool for combat severe-burn shock. • Quantifying AKI Impact on Warfighters: His research published in clinical literature systematically mapped how acute kidney failure acts as an independent driver of death in combat casualties. By applying standardized RIFLE/AKIN grading scales to military trauma databases, his work proved that severe AKI multi-organ complications drastically amplify ventilator dependencies and intensive care timelines. • The "Burn Navigator" Innovation: Beyond filtration hardware, Dr. Chung co-invented the Burn Resuscitation Decision Support System (Burn Navigator). This FDA-approved algorithmic tool assists frontline medics in delivering precision fluid resuscitation to critically burned casualties, preventing the run-away fluid volumes that historically triggered secondary abdominal compartment syndrome and acute kidney failure on the battlefield. This extensive military track record in controlling hyper-inflammation and organ failure directly underpins his current work implementing the QUELimmune selective cytopheretic filtration platforms for pediatric and adult critical care.

$ICU If both existing and future warrants are exercised, that will raise $9.48M and put the total outstanding shares at around 6.97M. Runway to get to Adult AKI results. Easy $250M market cap if not multiples of that. At $250M, with new outstanding share count, that would put share price at around $35.86 post dilution. Headed in the right direction folks. Load up at $3.60! Ten bagger minimum from here imho.

$ICU so guys Sparky Nikki ballbearer, unity, bullish I know I’m missing a few but would love to meat in Vegas next year when we hit $15-$20 Who’s in .

$ICU purchased another 30 % over last 2 days. Even before I saw the designation. Mostly because of what I stated in last. When something is effective and safe in peds, it will be so in adults. A 50x bigger Market. Dealing with hospitalizations and ICU admissions at various points in my career, this safe device has a real chance of becoming standard of care. Standard of care. Think a minute , Dtandard of care Just my opinion, but I am excited. Peace brothers and sisters.

$ICU $ICU 🚨 This is getting VERY interesting. A pre-specified sepsis analysis is already built into NEUTRALIZE-AKI, and SeaStar expects to present the data to the FDA in the near term. Now add a fresh Breakthrough Device Designation for adult sepsis. If that data hits, $ICU could move FAST. 🔥 The setup is getting harder to ignore. 🚀

$ICU The numbers on sepsis are staggering. One third of all global deaths are due to sepsis.128 million cases and 21.8 million deaths in 2019. Don’t know how many would benefit from the scd but only need a small percentage of the market to hit huge numbers.

$ICU So, now we have had the CEO reference one hospital about 3-4 months ago considering the SCD its internal "Standard of Care", and then you have the CFO referring just now to the SCD as the "future standard of care." People, the executive team would not be tossing around this term if they didn't really believe its going to happen. I am still amazed that we can buy shares down at these prices. Grabbed 3,000 more. I lost track but I think I got 5,000 or 6,000 today. GL next week going into investor conferences, and then the big conference on the 22nd!

$ICU well said!!! SEPSIS has been a big part of the Dr Chung Adult trial and now the market is starting to see the pieces of the puzzle. I need to see if we have a BDD for ARDS yet as this is also in the adult trial? Upside here is hard for most to comprehend. looking fwd to FDA SAVE news. We getting momentum, volume and many more catalysts coming. This one can shoot to a MC of over 100 million at any time IMO

$ICU A new BDD just for SEPSIS! 7 BDDs?!? Same device?! And a clean one, just for SEPSIS! The current adult study will have enough data on sepsis that this could sail through quickly. This is INSANELY undervalued. This will actually help big pharma save patients so they can then go on other medicines and treatments to address underlying conditions. Congratulations Seastar! (ICU) $JNJ $BDX $MDT $MRNA

$ICU seems like a few more whales like Sparky are starting to accumulate!!!! welcome bulls! the more dd you do- the more you will be buying!!!! zero doubt

$ICU Why Management Did It: While conventional retail shareholders often view massive warrant repricing as a "betrayal" due to the sudden stock drop, SeaStar's management team viewed it as a operational necessity. They traded a temporary stock decline for $3.3 million in immediate cash to fund the commercial roll-out of their QUELIMMUNE hyperinflammation therapy and advance FDA programs. In microcap biotech, having cash to survive the next 12 months is always prioritized over keeping short-term stock charts green.

$ICU ‘Dr. Chung continued, “This is now the seventh indication for which the SCD has received Breakthrough Device Designation. Each reflects the FDA’s determination that the applicable criteria have been met, including a reasonable expectation that the technology could provide more effective treatment for a life-threatening or irreversibly debilitating condition. We believe the breadth of these designations reinforces the disease-agnostic potential of the SCD platform to address dysregulated inflammation across multiple serious conditions, and we are committed to generating the clinical evidence needed to advance these indications.”’ nothing to see here! one device that has over 90 % margins has the potential to treat 7 issues!!!!

$ICU never seen a stock like this before. Even with no volume it holds. Year to date chart looks strong with high accumulation. The amount of lurking here is astronomical. Stock is poised to move up and end the day green here. 8 more trading days until SAVE data convinces patient’s parents and doctors to start using the SCD more regularly. Higher adoption through billing and reimbursement plus peds seminar approving continued use in Sept. Inflection point around the corner… holding without any reservations now.